Sirtex Medical Ltd

North Sydney, Australia

Sirtex Medical Ltd

North Sydney, Australia
SEARCH FILTERS
Time filter
Source Type

Patent
SIRTEX MEDICAL Ltd | Date: 2017-08-09

A device for transferring a toxic substance from a dispensing vessel to at least one receiving vessel comprising: (i) a receiving portion arranged to receive a dispensing vessel containing a toxic substance; and (ii) a transfer apparatus having a first infusion line adapted for fluid communication with the dispensing vessel to transfer a carrier fluid into said vessel and a second infusion line having one end adapted for fluid communication to withdraw and transfer the carrier fluid and the toxic substance from the dispensing vessel and the other end of the second infusion line arranged to connect with the at least one receiving vessel.


Patent
Sirtex Medical Ltd | Date: 2015-05-07

Accordingly, the present invention provides a method of treating kidney neoplasia in a subject in need of treatment, by subjecting the patient to SIRT.


Global Novel Drug Delivery Systems for Cancer Therapy Market by Technologies, Trends and Forecast to 2021, New Report by iHealthcareAnalyst, Inc. Novel Drug Delivery Systems for Cancer Therapy Market by Technology Types - Embolization Particles, Drug Eluting Beads, PVA Particles, Microspheres, Gelatin-Based, Selective Internal Radiation Therapy (SIRT), Therasphere, SIR-Spheres, Holmium-Based Microspheres, Liquid Embolics, Onyx (LES and HD-500), TRUFILL nBCA LES, and Nanoparticles and Forecast 2017-2021 Maryland Heights, MO, May 09, 2017 --( Browse Novel Drug Delivery Systems for Cancer Therapy Market by Technology Types - Embolization Particles, Drug Eluting Beads, PVA Particles, Microspheres, Gelatin-Based, Selective Internal Radiation Therapy (SIRT), Therasphere, SIR-Spheres, Holmium-Based Microspheres, Liquid Embolics, Onyx (LES and HD-500), TRUFILL nBCA LES, and Nanoparticles and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/novel-drug-delivery-systems-cancer-therapy-market/ The global novel drug delivery systems for cancer therapy market segmentation is based on technology types such as embolization particles, drug eluting beads, PVA particles, microspheres, gelatin-based, selective internal radiation therapy (SIRT), TheraSphere, SIR-Spheres, Holmium-based Microspheres, Liquid Embolics, Onyx (LES and HD-500), TRUFILL nBCA LES, and nanoparticles. The global novel drug delivery systems for cancer therapy market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global novel drug delivery systems for cancer therapy market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global novel drug delivery systems for cancer therapy market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. Major players operating in the global novel drug delivery systems for cancer therapy market and included in this report are Advanced Medical Isotope Corporation, Bind Therapeutics, Boston Scientific Corporation, BTG plc, CeloNova BioSciences, Inc., Cook Medical, Inc., Cospheric LLC, Covidien, plc, Eckert & Ziegler BEBIG, EmboMedics, Inc., Kobo Products, Inc., Merit Medical Systems, Inc., Mo-Sci Corporation, Nanobiotix, Polysciences, Inc., Sirtex Medical, Inc. and Terumo Medical Corporation. 1. Technology 1.1.1. Drug Eluting Beads 1.1.2. PVA particles, microspheres, gelatin-based 1.1.3. Selective Internal Radiation Therapy (SIRT) 1.1.4. TheraSphere 1.1.5. SIR-Spheres 1.1.6. Holmium-based Microspheres 1.1.7. Liquid Embolics 1.1.7.1. Onyx (LES and HD-500) 1.1.7.2. TRUFILL nBCA LES 1.1.8. Nanoparticles 2. Geography (Region, Country) 2.1. North America (U.S., Canada) 2.2. Latin America (Brazil, Mexico, Rest of LA) 2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 2.4. Asia Pacific (Japan, China, India, Rest of APAC) 2.5. Rest of the World 3. Company Profiles 3.1. Advanced Medical Isotope Corporation 3.2. Bind Therapeutics 3.3. Boston Scientific Corporation 3.4. BTG plc 3.5. CeloNova BioSciences, Inc. 3.6. Cook Medical, Inc. 3.7. Cospheric LLC 3.8. Covidien, plc 3.9. Eckert & Ziegler BEBIG 3.10. EmboMedics, Inc. 3.11. Kobo Products, Inc. 3.12. Merit Medical Systems, Inc. 3.13. Mo-Sci Corporation 3.14. Nanobiotix 3.15. Polysciences, Inc. 3.16. Sirtex Medical, Inc. 3.17. Terumo Medical Corporation To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/novel-drug-delivery-systems-cancer-therapy-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, May 09, 2017 --( PR.com )-- Novel drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. The novel drug delivery systems minimize drug degradation and loss, prevent harmful side-effects and increase drug bioavailability and the fraction of the drug accumulated in the required zone. A large variety of embolic agents are used by interventional radiologists for the selective occlusion of arteries supplying blood to tumors which depends on various factors including size of the vessel to be embolized, duration of the vessel to be occluded, desired clinical outcome and also the intrinsic properties and behavior of the agent.Browse Novel Drug Delivery Systems for Cancer Therapy Market by Technology Types - Embolization Particles, Drug Eluting Beads, PVA Particles, Microspheres, Gelatin-Based, Selective Internal Radiation Therapy (SIRT), Therasphere, SIR-Spheres, Holmium-Based Microspheres, Liquid Embolics, Onyx (LES and HD-500), TRUFILL nBCA LES, and Nanoparticles and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/novel-drug-delivery-systems-cancer-therapy-market/The global novel drug delivery systems for cancer therapy market segmentation is based on technology types such as embolization particles, drug eluting beads, PVA particles, microspheres, gelatin-based, selective internal radiation therapy (SIRT), TheraSphere, SIR-Spheres, Holmium-based Microspheres, Liquid Embolics, Onyx (LES and HD-500), TRUFILL nBCA LES, and nanoparticles.The global novel drug delivery systems for cancer therapy market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global novel drug delivery systems for cancer therapy market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global novel drug delivery systems for cancer therapy market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.Major players operating in the global novel drug delivery systems for cancer therapy market and included in this report are Advanced Medical Isotope Corporation, Bind Therapeutics, Boston Scientific Corporation, BTG plc, CeloNova BioSciences, Inc., Cook Medical, Inc., Cospheric LLC, Covidien, plc, Eckert & Ziegler BEBIG, EmboMedics, Inc., Kobo Products, Inc., Merit Medical Systems, Inc., Mo-Sci Corporation, Nanobiotix, Polysciences, Inc., Sirtex Medical, Inc. and Terumo Medical Corporation.1. Technology1.1.1. Drug Eluting Beads1.1.2. PVA particles, microspheres, gelatin-based1.1.3. Selective Internal Radiation Therapy (SIRT)1.1.4. TheraSphere1.1.5. SIR-Spheres1.1.6. Holmium-based Microspheres1.1.7. Liquid Embolics1.1.7.1. Onyx (LES and HD-500)1.1.7.2. TRUFILL nBCA LES1.1.8. Nanoparticles2. Geography (Region, Country)2.1. North America (U.S., Canada)2.2. Latin America (Brazil, Mexico, Rest of LA)2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)2.4. Asia Pacific (Japan, China, India, Rest of APAC)2.5. Rest of the World3. Company Profiles3.1. Advanced Medical Isotope Corporation3.2. Bind Therapeutics3.3. Boston Scientific Corporation3.4. BTG plc3.5. CeloNova BioSciences, Inc.3.6. Cook Medical, Inc.3.7. Cospheric LLC3.8. Covidien, plc3.9. Eckert & Ziegler BEBIG3.10. EmboMedics, Inc.3.11. Kobo Products, Inc.3.12. Merit Medical Systems, Inc.3.13. Mo-Sci Corporation3.14. Nanobiotix3.15. Polysciences, Inc.3.16. Sirtex Medical, Inc.3.17. Terumo Medical CorporationTo request Table of Contents and Sample Pages of this report visit:https://www.ihealthcareanalyst.com/report/novel-drug-delivery-systems-cancer-therapy-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com


"We performed a blinded evaluation of the extensive radiological database of the recently-reported SIRFLOX study to compare potential liver resectability at baseline and follow-up," said Dr. Benjamin Garlipp, the principal author of the REsect study and a liver surgeon at Otto-von-Guericke-Universität, Magdeburg, Germany. "We found that while resectability increased from baseline to follow-up in both the chemotherapy only arm and the chemotherapy + SIRT arm of the SIRFLOX study, the increase was significantly more pronounced in patients receiving the combination treatment - 38.1% of these were resectable on the basis of their liver CT scan at follow-up, compared to 28.9% of the patients receiving chemotherapy only (p<0.0001). This is an important finding because surgical resection is the mainstay of potentially curative treatments for these patients, and there is an increasing body of evidence suggesting that it can prolong their lives even though most of them eventually recur." Of the 472 SIRFLOX study patients whose pre- and post-treatment liver CT scans were evaluable by the REsect surgeons, 228 had received first-line mFOLFOX6 chemotherapy (± bevacizumab), while 244 were treated with the combination of chemotherapy and SIR-Spheres Y-90 resin microspheres.[1],[2] There was no significant difference in the resectability of the patients' liver metastases at baseline (11.0% vs. 11.9%; p=0.775). In a second analysis, of the patients who were deemed still unresectable at baseline, significantly more patients in the Y-90 resin microspheres group had resectable liver metastases compared to those who received chemotherapy alone (31.2% vs. 22.7%; p<0.0001).[1] The REsect study was conducted by a panel of 14 HPB (Hepato-Pancreato-Biliary) surgeons from leading medical centres in Belgium, France, Germany, Italy, The Netherlands, Spain, the UK and the USA.[1] Five surgeons performed independent, blinded analyses of 100 baseline and follow-up scans chosen at random from the 472 cases to be reviewed. Blinded analysis of the remaining scans was conducted of 22-25 cases at a time by three surgeons working independently and chosen at random from the nine other members of the REsect panel. The reviewers were blinded to patient identifiers, visit (baseline or follow-up), treatment and clinical information, as well as being blinded to the other reviewers' assessments. A patient was deemed to be resectable or unresectable by majority agreement (≥3 of 5 surgeons or ≥2 of 3 surgeons). "As a surgeon, it is always my aim to offer the option of a potentially curative liver resection to patients with mCRC. We know that in many patients with metastatic colorectal cancer the liver is the only organ with cancer deposits, and converting patients from a stage where resection of the disease is not possible into one where potential curative resection becomes an option again has an enormous impact for patients. This retrospective analysis suggests that SIRT with Y-90 resin microspheres could be a means to achieving resection for more of these patients," Dr Garlipp emphasized. What is SIRT with SIR-Spheres Y-90 resin microspheres? SIRT with SIR-Spheres Y-90 resin microspheres is an approved treatment for inoperable liver tumours. It is a minimally-invasive treatment that delivers high doses of high-energy beta radiation directly to the tumours. SIRT is administered to patients by interventional radiologists, who infuse millions of radioactive resin microspheres (diameter between 20-60 microns) via a catheter into the liver arteries that supply blood to the tumours. By using the tumours' blood supply, the microspheres selectively target liver tumours with a dose of radiation that is up to 40 times higher than conventional radiotherapy, while sparing healthy tissue. SIR-Spheres Y-90 resin microspheres are approved for use in Argentina, Australia, Brazil, the European Union (CE Mark), Switzerland, Turkey, and several countries in Asia for the treatment of unresectable liver tumours. In the US, SIR-Spheres Y-90 resin microspheres have a Pre-Market Approval (PMA) from the FDA and are indicated for the treatment of unresectable metastatic liver tumours from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (floxuridine). Sirtex Medical Limited (ASX: SRX) is an Australian-based global healthcare business working to improve treatment outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres Y-90 resin microspheres. Approximately 73,000 doses have been supplied to treat patients with liver cancer at more than 1060 medical centres in over 40 countries. For more information, please visit http://www.sirtex.com . SIR-Spheres® is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd. Further materials can be found at: www.sirtex.com/media.


Patent
SIRTEX MEDICAL Ltd | Date: 2017-03-15

Accordingly, the present invention provides a method of treating kidney neoplasia in a subject in need of treatment, by subjecting the patient to SIRT.


Patent
Sirtex Medical Ltd | Date: 2013-08-16

The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix and stably incorporated radionuclide, processes for its production and a method of radiation therapy utilising the particulate material.


Patent
SIRTEX MEDICAL Ltd | Date: 2015-01-23

A method of treating cancer in a patient comprising administering to the patient an a systemic chemotherapeutic drug regime in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have an improved anticancer effect.


Patent
SIRTEX MEDICAL Ltd | Date: 2016-06-15

The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising a polymeric matrix and stably incorporated radionuclide, processes for its production and a method of radiation therapy utilising the particulate material.


Patent
Sirtex Medical Ltd | Date: 2014-05-15

A microparticle composition(s) comprising nanomagnetic particles and a matrix, wherein said microparticle composition(s) have a least one of the following properties: (a) a VAR of at least about 1 Watts/cm3 subject to appropriate field conditions; (b) a density of about 2.7 or less: or (c) a size of about 100 nm to about 200 microns.


Patent
Sirtex Medical Ltd | Date: 2015-07-07

Accordingly, the present invention provides a method of treating lung neoplasia in a subject in need of treatment, by subjecting the patient to SIRT.

Loading Sirtex Medical Ltd collaborators
Loading Sirtex Medical Ltd collaborators